TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS

The present invention relates to the treatment of cutaneous lupus erythematosus. The problem to be solved by the invention is to provide a new pharmaceutical use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1- yl]-3-oxopropanenitrile. A therapeutic or preventiv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	NIELSEN, JACOB, REFER, PIA KLIE, MORTENSEN, HELENE, SANDER, CAMILLA, PEDERSEN, GITTE POMMERGAARD
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the treatment of cutaneous lupus erythematosus. The problem to be solved by the invention is to provide a new pharmaceutical use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1- yl]-3-oxopropanenitrile. A therapeutic or preventive agent cutaneous lupus erythematosus, containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile as an active ingredient, and a pharmaceutical formulation thereof. La présente invention concerne le traitement du lupus érythémateux cutané. Le problème à résoudre par l'invention est de fournir une nouvelle utilisation pharmaceutique du 3-[(3S,4R)-3-méthyl-6-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1,6-diazaspiro [3,4] octan-1-yl]-3-oxopropanenitrile. L'invention concerne un agent thérapeutique ou préventif du lupus érythémateux cutané, contenant du 3- [(3S,4R)-3-méthyl-6-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3,4] octan-1-yl]-3-oxopropanenitrile en tant que principe actif, et une formulation pharmaceutique de celui-ci.